Dr. Michael E. Dever

Internal Medicine
618 E South St, Ste 100, 
Orlando, FL 
618 E South St, Ste 100, 
Orlando, FL 

Overview

Michael Dever is a primary care provider, practicing in Internal Medicine in Orlando, Florida.

His clinical expertise encompasses Pericarditis.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 9 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

CNS Healthcare
618 E South St, Ste 100, Orlando, FL 32801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in Restless Legs Syndrome Patients With Iron-deficiency Anemia
Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in Restless Legs Syndrome Patients With Iron-deficiency Anemia
Enrollment Status: Terminated
Publish Date: April 11, 2025
Intervention Type: Drug
Study Drug: Ferric Carboxymaltose
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.
Enrollment Status: Terminated
Publish Date: April 02, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
Enrollment Status: Completed
Publish Date: January 14, 2020
Intervention Type: Genetic
Study Phase: Not Applicable
View 7 Less Clinical Trials

3 Total Publications

Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years Old.
Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years Old.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 06, 2025
Similar Doctors
Expertise in
8
conditions
Dr. Richard Pratley
Internal Medicine
Expertise in
8
conditions
Dr. Richard Pratley
Internal Medicine

Office

2415 N Orange Ave Ste 502, 
Orlando, FL 
 (8.8 miles away)
407-303-2801
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Pratley is an Internal Medicine provider practicing medicine in Orlando, Florida. Dr. Pratley is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Low Blood Sugar, Type 1 Diabetes (T1D), and Maturity Onset Diabetes of the Young.

Expertise in
43
conditions
Dr. Brian Masters
Internal Medicine
Expertise in
43
conditions
Dr. Brian Masters
Internal Medicine

AdventHealth Orlando

601 E Rollins St, 
Orlando, FL 
 (10.0 miles away)
407-622-2222
Languages Spoken:
English
See accepted insurances

Brian Masters is a primary care provider, practicing in Internal Medicine in Orlando, Florida. Dr. Masters is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Subdural Hematoma, Stroke, Cerebral Arteriovenous Malformation, Microdiscectomy, and Cervical Disc Surgery.

Expertise in
40
conditions
Dr. Pankaj Bansal
Internal Medicine
Expertise in
40
conditions
Dr. Pankaj Bansal
Internal Medicine

Orlando Arthritis And Rheumatology Clinic

7932 Sand Lake Rd, Suite 200, 
Orlando, FL 
 (4.1 miles away)
407-355-7759
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Pankaj Bansal is an Internal Medicine provider practicing medicine in Orlando, Florida. Dr. Bansal is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus (SLE), and Discoid Lupus Erythematosus (DLE). Dr. Bansal is board certified in Rheumatology - American Board Of Internal Medicine. Dr. Bansal is currently accepting new patients.

Frequently Asked Questions about Dr. Michael E. Dever

How do I make an appointment with Dr. Michael E. Dever?

You can book an appointment with Dr. Michael E. Dever by calling their office at 407-425-5100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael E. Dever a top-rated expert for Pericarditis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael E. Dever is classified as an Experienced expert for Pericarditis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael E. Dever specialize in?

While Dr. Michael E. Dever is a Internal Medicine, they have specific expertise in Pericarditis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Michael E. Dever participate in research or clinical trials?

Yes. Dr. Michael E. Dever has published 3 articles and abstracts on conditions like Pericarditis. You can view a list of Dr. Michael E. Dever's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael E. Dever accept my insurance?

Dr. Michael E. Dever accepts most major insurance plans, including Anthem BCBS and Cigna. We recommend calling the office directly at 407-425-5100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dever's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile